I can't see that being anything but great news, or they wouldn't add risk. It's working. The doctors are telling other patients and the company. And the patients are begging for it because this study is only for patients who have tried EVERYTHING else. Fantastic find. Still expecting volatility but a heckuva spike into results and beyond. Thanks, Mitch.
Good post, Tursta. There is a lot of enthusiasm with IDRA, and I view it as a long-term grandslam. However, there is heavy short interest in the interim. GSO's will send this to the moon forever. but the IND work won't be done until next year. It starts 2H2015 per 10Q. They do have long history of 2nd gen data and its pioneer to shorten this. I think 1H2016 into the clinic with Phase 1/2 results 2016-2017. By then, Phase 3 will be done for WM, DLBCL, Dermotomyositis, and collaboration trials. I'm exercising patience with this diamond and averaging down when big-money shorts drive it that way. Use 'em.
could be, johny. would not surprise me. How low you gonna drive this? i want in at 2.50
Thought it was easy money
Less immunotoxicity and vastly improved delivery. Agrawal, our president and pioneer of GSO 2 AND 3, has repeatedly called GSO 3 "picture perfect". And it's been independently verified by 3rd parties. I'll go with his take on 3rd-gen GSO and wait for $50 whether it's next year or 2017. In the meantime, please drive it down because I need more time to accumulate. Not even close to being finished.
We're gonna dwarf that, MGM. Thanks for pointing it out. It's gonna move fast and sharply higher when the move starts.
Yep, it's all about the fundamentals. I find myself getting excited when the price drops now, so I can accumulate somewhere near your holdings. Vision.
Hey Eduardo. I'm appreciating the time to add. My target is 30 by end of 2017. Think your 20 will come next year. Patience will be rewarded as you well know.
"IMO-9200 for Autoimmune Disease. We have developed a second novel synthetic oligonucleotide antagonist of TLR7, TLR8, and TLR9, IMO-9200, as a drug candidate in clinical development for potential use in selected autoimmune disease indications. In October 2014, we initiated subcutaneous dosing in a Phase 1 clinical trial of IMO-9200. We have also initiated additional preclinical studies of IMO-9200 for a selected autoimmune disease."
Could be saving it for AACR. That's where the company has historically made there announcements and presentations of data. I believe 9200 will be the next piece of news. Milano knows exactly what he's doing. Last 2 orphan announcements came out of left field. An announcement re 9200 and indication such as lupus, accompanied by data which is due now, AND a partner. Let's just say that will wipe out the shorts' 10-cent profit and then some.
Runs this Saturday through next Wednesday. Take advantage of the shorting and buy the daily lows. They will be covering for a higher price. We could get 9200 or combo news next week. GL longs.